Editorial Commentary: The New Acinetobacter Equation: Hypervirulence Plus Antibiotic Resistance Equals Big Trouble

Clinical Infectious Diseases

Volumn 61, Issue 2, 2015, Pages 155-156

  Paterson, David L ^a   Harris, Patrick N A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

acinetobacter; carbapenem resistance; virulence

Indexed keywords

ANTIBIOTIC AGENT; AVIBACTAM PLUS CEFTAZIDIME; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CARRIER PROTEIN; CEFTOLOZANE PLUS TAZOBACTAM; ERAVACYCLINE; POLYMYXIN; POLYMYXIN DERIVATIVE; SUCCINATE DEHYDROGENASE (UBIQUINONE); TIGECYCLINE; VIRULENCE FACTOR;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; COMMUNITY ACQUIRED PNEUMONIA; GENE CLUSTER; GENE EXPRESSION; GENOMICS; HEALTHCARE ASSOCIATED INFECTION; HOSPITAL ADMISSION; HUMAN; INFECTION CONTROL; INTENSIVE CARE UNIT; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; RESPIRATORY SYSTEM; TYPE VI SECRETION SYSTEM; ACINETOBACTER INFECTIONS; ANIMAL; EPIDEMIC; FEMALE; MALE; MORTALITY; MULTIDRUG RESISTANCE; PATHOGENICITY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; DISEASE OUTBREAKS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE;

EID: 84936762784     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ227     Document Type: Note

References (10)

1. Doi Y, Murray GL, Peleg AY. Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med 2015; 36:85-98.
2. Jones CL, Clancy M, Honnold C, et al. A fatal outbreak of an emerging clone of extensively drug-resistant Acinetobacter baumannii with enhanced virulence. Clin Infect Dis 2015; 61:145-54.
3. Davis JS, McMillan M, Swaminathan A, et al. A 16-year prospective study of communityonset bacteremic Acinetobacter pneumonia: low mortality with appropriate initial empirical antibiotic protocols. Chest 2014; 146: 1038-45.
4. Farrugia DN, Elbourne LD, Hassan KA, et al. The complete genome and phenome of a community-acquired Acinetobacter baumannii. PloS One 2013; 8:e58628.
5. Whitman TJ, Qasba SS, Timpone JG, et al. Occupational transmission of Acinetobacter baumannii from a United States serviceman wounded in Iraq to a health care worker. Clin Infect Dis 2008; 47:439-43.
6. Patel G, Perez F, Hujer AM, et al. Fulminant endocarditis and disseminated infection caused by carbapenem-resistant Acinetobacter baumannii in a renal-pancreas transplant recipient. Transpl Infect Dis 2015; 17:289-96.
7. Bruhn KW, Pantapalangkoor P, Nielsen T, et al. Host fate is rapidly determined by innate effector-microbial interactions during Acinetobacter baumannii bacteremia. J Infect Dis 2015; 211:1296-305.
8. Gottig S, Gruber TM, Higgins PG, Wachsmuth M, Seifert H, Kempf VA. Detection of pan drug-resistant Acinetobacter baumannii in Germany. J Antimicrob Chemother 2014; 69:2578-9.
9. Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J. Activity of eravacycline against enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother 2015; 59:1802-5.
10. Russo TA, Page MG, Beanan JM, et al. In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii. J Antimicrob Chemother 2011; 66:867-73.